rabbit polyclonal anti glucose transporter glut3 antibody (Danaher Inc)
Danaher Inc is a verified supplier 
Danaher Inc manufactures this product 
86
Structured Review
Danaher Inc
rabbit polyclonal anti glucose transporter glut3 antibody
![(A) Volcano plot derived from bulk RNA-seq data collected from PDGCs lentivirally infected with the SCR or CD97 shRNA (n = 3 biological replicates for each). Genes involved in canonical glycolysis and glucose transport are represented as large yellow points. Genes involved in the TCA cycle and OXPHOS (cytochrome oxidase subunits) are represented as large green points. CD97 is represented by an orange point. (B) The top ten enriched and depleted pathways determined by the largest fold enrichment among downregulated genes using GO PANTHER pathway enrichment analysis. Stars indicate metabolic pathways. (C) Correlation matrix from bulk RNA-seq data collected from PDGCs following knockdown or overexpression of CD97 shows high correlation between CD97 and glycolysis-related genes and anti-correlation with TCA cycle-related genes. HK2 (hexokinase 2) and SLC2A3 (glucose transporter 3 <t>[GLUT3])</t> transcripts are both included because they have been implicated in Warburg metabolism. (D) Bar graph showing decreased lactate production after knockdown of CD97 (n = 6 per PDGC; two-way ANOVA F 1,15 = 27.24, p < 0.001) and increased lactate production after CD97 overexpression in PDGCs (n = 3 per PDGC; two-way ANOVA F 1,6 = 26.07, p < 0.01). (E) Steady-state metabolomic data reveal depletion of glycolytic metabolites after knockdown of CD97 in PDGCs (PN [proneural], n = 2–3 [one replicate was removed for technical reasons]; CL [classical], n = 3). (F) Depleted (red) and enriched (green) heavy-labeled glycolytic and TCA cycle metabolites after a heavy-labeled glucose tracing experiment. (G) Representative Seahorse Cell Energy Phenotype graph showing OCR and ECAR changes before (baseline) and after (maximal) addition of mitochondrial stressors. (H and I) Bar graphs quantifying baseline and maximal ECAR (n = 6 per PDGC; baseline: two-way ANOVA F 1,10 = 14.06; **p < 0.01; maximal: two-way ANOVA F 1,10 = 17.87, p < 0.01). (J and K) Bar graphs quantifying baseline and maximal OCR (n = 6 per PDGC; baseline: two-way ANOVA F 1,10 = 2.820, p > 0.05; maximal: two-way ANOVA F 1,10 = 5.474; *p < 0.05). Error bars indicate SEM.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_1603/pmc10841603/pmc10841603__nihms-1948162-f0004.jpg)
Rabbit Polyclonal Anti Glucose Transporter Glut3 Antibody, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+polyclonal+anti+glucose+transporter+glut3+antibody/pmc10841603-19-0-8
Average 86 stars, based on 1 article reviews
Rabbit Polyclonal Anti Glucose Transporter Glut3 Antibody, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+polyclonal+anti+glucose+transporter+glut3+antibody/pmc10841603-19-0-8
Average 86 stars, based on 1 article reviews
rabbit polyclonal anti glucose transporter glut3 antibody - by Bioz Stars,
2026-09
86/100 stars
Images
1) Product Images from "The expression profile and tumorigenic mechanisms of CD97 (ADGRE5) in glioblastoma render it a targetable vulnerability"
Article Title: The expression profile and tumorigenic mechanisms of CD97 (ADGRE5) in glioblastoma render it a targetable vulnerability
Journal: Cell reports
doi: 10.1016/j.celrep.2023.113374
Figure Legend Snippet: (A) Volcano plot derived from bulk RNA-seq data collected from PDGCs lentivirally infected with the SCR or CD97 shRNA (n = 3 biological replicates for each). Genes involved in canonical glycolysis and glucose transport are represented as large yellow points. Genes involved in the TCA cycle and OXPHOS (cytochrome oxidase subunits) are represented as large green points. CD97 is represented by an orange point. (B) The top ten enriched and depleted pathways determined by the largest fold enrichment among downregulated genes using GO PANTHER pathway enrichment analysis. Stars indicate metabolic pathways. (C) Correlation matrix from bulk RNA-seq data collected from PDGCs following knockdown or overexpression of CD97 shows high correlation between CD97 and glycolysis-related genes and anti-correlation with TCA cycle-related genes. HK2 (hexokinase 2) and SLC2A3 (glucose transporter 3 [GLUT3]) transcripts are both included because they have been implicated in Warburg metabolism. (D) Bar graph showing decreased lactate production after knockdown of CD97 (n = 6 per PDGC; two-way ANOVA F 1,15 = 27.24, p < 0.001) and increased lactate production after CD97 overexpression in PDGCs (n = 3 per PDGC; two-way ANOVA F 1,6 = 26.07, p < 0.01). (E) Steady-state metabolomic data reveal depletion of glycolytic metabolites after knockdown of CD97 in PDGCs (PN [proneural], n = 2–3 [one replicate was removed for technical reasons]; CL [classical], n = 3). (F) Depleted (red) and enriched (green) heavy-labeled glycolytic and TCA cycle metabolites after a heavy-labeled glucose tracing experiment. (G) Representative Seahorse Cell Energy Phenotype graph showing OCR and ECAR changes before (baseline) and after (maximal) addition of mitochondrial stressors. (H and I) Bar graphs quantifying baseline and maximal ECAR (n = 6 per PDGC; baseline: two-way ANOVA F 1,10 = 14.06; **p < 0.01; maximal: two-way ANOVA F 1,10 = 17.87, p < 0.01). (J and K) Bar graphs quantifying baseline and maximal OCR (n = 6 per PDGC; baseline: two-way ANOVA F 1,10 = 2.820, p > 0.05; maximal: two-way ANOVA F 1,10 = 5.474; *p < 0.05). Error bars indicate SEM.
Techniques Used: Derivative Assay, RNA Sequencing Assay, Infection, shRNA, Over Expression, Labeling
Figure Legend Snippet:
Techniques Used: Recombinant, Modification, Disruption, Activation Assay, Knock-Out, shRNA
Related Articles
Derivative Assay:Article Title: The expression profile and tumorigenic mechanisms of CD97 (ADGRE5) in glioblastoma render it a targetable vulnerability Article Snippet: RNA Sequencing Assay:Article Title: The expression profile and tumorigenic mechanisms of CD97 (ADGRE5) in glioblastoma render it a targetable vulnerability Article Snippet: Infection:Article Title: The expression profile and tumorigenic mechanisms of CD97 (ADGRE5) in glioblastoma render it a targetable vulnerability Article Snippet: shRNA:Article Title: The expression profile and tumorigenic mechanisms of CD97 (ADGRE5) in glioblastoma render it a targetable vulnerability Article Snippet: Over Expression:Article Title: The expression profile and tumorigenic mechanisms of CD97 (ADGRE5) in glioblastoma render it a targetable vulnerability Article Snippet: Labeling:Article Title: The expression profile and tumorigenic mechanisms of CD97 (ADGRE5) in glioblastoma render it a targetable vulnerability Article Snippet: Recombinant:Article Title: The expression profile and tumorigenic mechanisms of CD97 (ADGRE5) in glioblastoma render it a targetable vulnerability Article Snippet: Modification:Article Title: The expression profile and tumorigenic mechanisms of CD97 (ADGRE5) in glioblastoma render it a targetable vulnerability Article Snippet: Disruption:Article Title: The expression profile and tumorigenic mechanisms of CD97 (ADGRE5) in glioblastoma render it a targetable vulnerability Article Snippet: Activation Assay:Article Title: The expression profile and tumorigenic mechanisms of CD97 (ADGRE5) in glioblastoma render it a targetable vulnerability Article Snippet: Knock-Out:Article Title: The expression profile and tumorigenic mechanisms of CD97 (ADGRE5) in glioblastoma render it a targetable vulnerability Article Snippet: |